Neoral-Sandimmun 100 mg/ml or. sol. Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neoral-sandimmun 100 mg/ml or. sol.

novartis pharma sa-nv - ciclosporin 100 mg - oral solution - 100 mg/ml - ciclosporin 100 mg/ml - ciclosporin

Atopica 100 mg/ml or. sol. Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

atopica 100 mg/ml or. sol.

elanco gmbh - ciclosporin 100 mg/ml - oral solution - 100 mg/ml - ciclosporin 100 mg/ml - ciclosporin - cat; dog

Cyclavance 100 mg/ml or. sol. Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cyclavance 100 mg/ml or. sol.

virbac s.a. - ciclosporin 100 mg/ml - oral solution - 100 mg/ml - ciclosporin 100 mg/ml - ciclosporin - dog; cat

Modulis 100 mg/ml or. sol. Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

modulis 100 mg/ml or. sol.

ceva santé animale sa-nv - ciclosporin 100 mg/ml - oral solution - 100 mg/ml - ciclosporin 100 mg/ml - ciclosporin - dog

Neoral-Sandimmun 100 mg soft caps. Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neoral-sandimmun 100 mg soft caps.

novartis pharma sa-nv - ciclosporin 100 mg - capsule, soft - 100 mg - ciclosporin 100 mg - ciclosporin

Atopica 100 mg soft caps. Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

atopica 100 mg soft caps.

elanco gmbh - ciclosporin 100 mg - capsule, soft - 100 mg - ciclosporin 100 mg - ciclosporin - dog

NEORAL ciclosporin 100mg capsule blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

neoral ciclosporin 100mg capsule blister pack

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg - capsule, soft - excipient ingredients: ethanol; iron oxide black; propylene glycol; gelatin; glycerol; peg-40 hydrogenated castor oil; titanium dioxide; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cystostatic drugs have failed, or are not tolerated, or are considered inapropriate, and when renal function is unimpaired (see warnings). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. additional indications from 11 june 1997: for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.

Neoral Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

neoral

novartis new zealand ltd - ciclosporin 100 mg/ml;   - oral solution - 100 mg/ml - active: ciclosporin 100 mg/ml   excipient: corn oil dl-alpha tocopherol ethanol polyethylene glycol hydrogenated castor oil propylene glycol - transplantation indications solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

Neoral Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

neoral

novartis new zealand ltd - ciclosporin 100mg;   - soft gelatin capsule - 100 mg - active: ciclosporin 100mg   excipient: corn oil dl-alpha tocopherol ethanol gelatin glycerol iron oxide black polyethylene glycol hydrogenated castor oil propylene glycol   titanium dioxide - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

NEORAL ciclosporin 100mg/mL oral liquid bottle Ástralía - enska - Department of Health (Therapeutic Goods Administration)

neoral ciclosporin 100mg/ml oral liquid bottle

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: dl-alpha-tocopherol; ethanol; corn glycerides; propylene glycol; peg-40 hydrogenated castor oil - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cystostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see warnings). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. additional indication from 11 june 1997: for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.